Aktuellt
SENASTE
The underlying performance of BB Biotech’s portfolio and thus NAV was boosted by its large cap holdings during 2022, but was held back by the small and mid-cap companies. During 2022, some of the smaller biotechs in the portfolio raised funds from licensing deals with larger companies in order to avoid dilutive equity funding.
LÄS MER
